JACQUELYNNE KIMANI: Open Payments
NPI 1043808454 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,904 in 240 payments from 15 companies in 2025. Trend: 2023 $3,779 · 2024 $3,366 · 2025 $4,904
Food & beverage: $4,656Education: $248
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 98 | $2,011 |
| Janssen Pharmaceuticals, Inc | 15 | $482 |
| Alkermes, Inc. | 18 | $463 |
| Otsuka America Pharmaceutical, Inc. | 34 | $442 |
| ABBVIE INC. | 29 | $376 |
| Vanda Pharmaceuticals Inc. | 14 | $273 |
| E.R. Squibb & Sons, L.L.C. | 5 | $246 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $177 |
| Supernus Pharmaceuticals, Inc. | 5 | $99 |
| Axsome Therapeutics, Inc. | 3 | $82 |
Products named: AUSTEDO XR, UZEDY, REXULTI, VRAYLAR, INVEGA SUSTENNA, ARISTADA, FANAPT, COBENFY.
Industry payments across MA — which companies pay providers there.
